Cancer Stem Cell for Tumor Therapy

被引:23
|
作者
Huang, Binjie [1 ,2 ]
Yan, Xin [1 ,2 ]
Li, Yumin [1 ,2 ]
机构
[1] Lanzhou Univ, Hosp 2, Dept Gen Surg, Lanzhou 730030, Peoples R China
[2] Lanzhou Univ, Hosp 2, Key Lab Digest Syst Tumors Gansu Prov, Lanzhou 730030, Peoples R China
基金
中国国家自然科学基金;
关键词
CSCs; mitotic division pattern; metabolic phenotype; therapeutic resistance; targeted strategy; tumor therapy; GAMMA-SECRETASE INHIBITOR; NEGATIVE BREAST-CANCER; EPITHELIAL-MESENCHYMAL TRANSITION; ACUTE MYELOID-LEUKEMIA; OVARIAN-CANCER; DLL4; BLOCKADE; STROMAL CELLS; PHASE-II; CD44; EXPRESSION;
D O I
10.3390/cancers13194814
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary: Although many methods have been applied in clinical treatment for tumors, they still always show a poor prognosis. Molecule targeted therapy has revolutionized tumor therapy, and a proper target must be found urgently. With a crucial role in tumor development, metastasis and recurrence, cancer stem cells have been found to be a feasible and potential target for tumor therapy. We list the unique biological characteristics of cancer stem cells and summarize the recent strategies to target cancer stem cells for tumor therapy, through which we hope to provide a comprehensive understanding of cancer stem cells and find a better combinational strategy to target cancer stem cells for tumor therapy. Tumors pose a significant threat to human health. Although many methods, such as operations, chemotherapy and radiotherapy, have been proposed to eliminate tumor cells, the results are unsatisfactory. Targeting therapy has shown potential due to its specificity and efficiency. Meanwhile, it has been revealed that cancer stem cells (CSCs) play a crucial role in the genesis, development, metastasis and recurrence of tumors. Thus, it is feasible to inhibit tumors and improve prognosis via targeting CSCs. In this review, we provide a comprehensive understanding of the biological characteristics of CSCs, including mitotic pattern, metabolic phenotype, therapeutic resistance and related mechanisms. Finally, we summarize CSCs targeted strategies, including targeting CSCs surface markers, targeting CSCs related signal pathways, targeting CSC niches, targeting CSC metabolic pathways, inducing differentiation therapy and immunotherapy (tumor vaccine, CAR-T, oncolytic virus, targeting CSCs-immune cell crosstalk and immunity checkpoint inhibitor). We highlight the potential of immunity therapy and its combinational anti-CSC therapies, which are composed of different drugs working in different mechanisms.
引用
收藏
页数:25
相关论文
共 50 条
  • [31] Tumor suppressor control of the cancer stem cell niche
    Kramer, K.
    Wu, J.
    Crowe, D. L.
    ONCOGENE, 2016, 35 (32) : 4165 - 4178
  • [32] Tumor Microenvironment: A Niche for Cancer Stem Cell Immunotherapy
    Mia C. Borlongan
    Dipongkor Saha
    Hongbin Wang
    Stem Cell Reviews and Reports, 2024, 20 : 3 - 24
  • [33] Tumor Oncogenotypes and Lung Cancer Stem Cell Identity
    Sullivan, James P.
    Minna, John D.
    CELL STEM CELL, 2010, 7 (01) : 2 - 4
  • [34] Identification and Characterization of the Wilms Tumor Cancer Stem Cell
    Petrosyan, Astgik
    Villani, Valentina
    Aguiari, Paola
    Thornton, Matthew E.
    Wang, Yizhou
    Rajewski, Alex
    Zhou, Shengmei
    Cravedi, Paolo
    Grubbs, Brendan H.
    De Filippo, Roger E.
    Sedrakyan, Sargis
    Lemley, Kevin V.
    Csete, Marie
    Da Sacco, Stefano
    Perin, Laura
    ADVANCED SCIENCE, 2023, 10 (20)
  • [35] Tumor Microenvironment: A Niche for Cancer Stem Cell Immunotherapy
    Borlongan, Mia C.
    Saha, Dipongkor
    Wang, Hongbin
    STEM CELL REVIEWS AND REPORTS, 2024, 20 (01) : 3 - 24
  • [36] Cancer stem cell characteristics of circulating tumor cells
    Tinhofer, Ingeborg
    Saki, Mohammad
    Niehr, Franlziska
    Keilholz, Ulrich
    Budach, Volker
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2014, 90 (08) : 622 - 627
  • [37] Cancer stem cell elimination to eradicate whole tumor
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (04) : 350 - 351
  • [38] Tumor heterogeneity driven by cancer stem cell markers
    Miyoshi, Norikatsu
    Fujino, Shiki
    Ogino, Takayuki
    Takahashi, Hidekazu
    Uemura, Mamoru
    Yamamoto, Hirofumi
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Eguchi, Hidetoshi
    CANCER SCIENCE, 2021, 112 : 376 - 376
  • [39] Tumor cell plus stem cell = Tumor stem cells
    不详
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2007, 45 (12): : B6 - B6
  • [40] Concerns about targeting cancer stem cell for cancer therapy
    Yang, Guodong
    Lu, Xiaozhao
    Fu, Haiyan
    Jin, Liang
    Yao, Libo
    Lu, Zifan
    MEDICAL HYPOTHESES, 2011, 76 (03) : 457 - 457